Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling
Read More Pharma Industry News GlycoNex and Nippon Kayaku team up to advance next-generation ADC candidate GNX201-ADC in solid tumours GlycoNex (4168) and Nippon Kayaku advance GNX201-ADC, a protease-activated ADC targeting solid tumours. Discover what this deal means for oncology. Read more. byVenkateshMarch 24, 2026